These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21083589)

  • 1. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
    Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
    Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
    Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
    Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
    Patel K; Benhamou Y; Yoshida EM; Kaita KD; Zeuzem S; Torbenson M; Pulkstenis E; Subramanian GM; McHutchison JG
    J Viral Hepat; 2009 Mar; 16(3):178-86. PubMed ID: 19175870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection.
    Paunovic K; Stojanovic M; Dimitrijevic Z; Paunovic G; Djordjevic V; Konstantinovic L; Kostic S
    Med Arch; 2012; 66(4):226-30. PubMed ID: 22919875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
    Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
    Knop V; Hofmann WP; Buggisch P; Klinker H; Mauss S; Günther R; Hinrichsen H; Hüppe D; Pfeiffer-Vornkahl H; Simon KG; Berg T; Manns MP; Friedrich-Rust M;
    J Viral Hepat; 2019 Feb; 26(2):224-230. PubMed ID: 30315694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
    Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
    J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
    Abuelhassan WB; Gasim GI; Ally R; Menezes C
    S Afr Med J; 2020 Aug; 110(9):920-925. PubMed ID: 32880279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C?
    Thandassery RB; Al Kaabi S; Soofi ME; Mohiuddin SA; John AK; Al Mohannadi M; Al Ejji K; Yakoob R; Derbala MF; Wani H; Sharma M; Al Dweik N; Butt MT; Kamel YM; Sultan K; Pasic F; Singh R
    J Clin Gastroenterol; 2016 Jul; 50(6):518-23. PubMed ID: 26974762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of selected laboratory markers of liver fibrosis in patients with chronic hepatitis type C].
    Kuśnierz-Cabala B; Solnica B; Mach T; Biesiada G; Dumnicka P
    Przegl Lek; 2010; 67(7):450-3. PubMed ID: 21387753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
    Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results.
    Başar O; Yimaz B; Ekiz F; Giniş Z; Altinbaş A; Aktaş B; Tuna Y; Çoban S; Delibaş N; Yüksel O
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):152-8. PubMed ID: 23391746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.
    Lackner C; Struber G; Liegl B; Leibl S; Ofner P; Bankuti C; Bauer B; Stauber RE
    Hepatology; 2005 Jun; 41(6):1376-82. PubMed ID: 15915455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
    El Raziky M; Elsharkawy A; Said SE; Abdelatty S; El Akel W; Tantawy O; Gamal Eldeen H; Mabrouk M
    J Interferon Cytokine Res; 2015 Aug; 35(8):649-53. PubMed ID: 25973761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acoustic radiation force impulse elastography and serum fibrosis markers in chronic hepatitis C.
    Silva Junior RG; Schmillevitch J; Nascimento Mde F; Miranda ML; Brant PE; Schulz PO; Vieira A; Szutan LA
    Scand J Gastroenterol; 2014 Aug; 49(8):986-92. PubMed ID: 24742130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.